$SIA (C6L.SG)$ Another year has passed, you're still so bad. What are you up to?
Translated
3
3
101682201-dna
liked
$Cassava Sciences (SAVA.US)$ After announcing the bad news, why are they keeping quiet on the next course of action? They owe shareholders and even their own workers an explanation how they intend to move forward….
4
101682201-dna
liked and commented on
$Cassava Sciences (SAVA.US)$
This one hurt! I had almost all my eggs in one basket. This was bad. I know a lot of us have family members suffering from Alzheimer's so it really was a double edged sword. Remember everyone do not let money dictate your happiness. Lock in on the other things that matter and shake this off. I have definitely learned lessons from this and am gonna change investing strategies moving forward with the pennies I have left.
Wish you all the best!
This one hurt! I had almost all my eggs in one basket. This was bad. I know a lot of us have family members suffering from Alzheimer's so it really was a double edged sword. Remember everyone do not let money dictate your happiness. Lock in on the other things that matter and shake this off. I have definitely learned lessons from this and am gonna change investing strategies moving forward with the pennies I have left.
Wish you all the best!
10
2
101682201-dna
commented on
2
101682201-dna
commented on
$Cassava Sciences (SAVA.US)$ Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary Endpoints
3 MINUTES AGO, 7:30 AM EST
VIA GLOBENEWSWIRE
Simufilam did not show a significant reduction in cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer's disease in the ReThink-ALZ Phase 3 study
Simufilam continued to demonstrate an overall favorable safety profile
Cassava intends to present the data at an upcoming medical meeting
The Company will hold a webca...
3 MINUTES AGO, 7:30 AM EST
VIA GLOBENEWSWIRE
Simufilam did not show a significant reduction in cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer's disease in the ReThink-ALZ Phase 3 study
Simufilam continued to demonstrate an overall favorable safety profile
Cassava intends to present the data at an upcoming medical meeting
The Company will hold a webca...
13
101682201-dna
liked
$Cassava Sciences (SAVA.US)$Here's what's happening, Allegedly... It looks like Robinhood has the 24 hours now for those HF/ shorts who are on Robinhood to try to cover before 4AM opens up to other platforms. All you other shorts who don't have access and have to wait to clear out your position at what price when it moves up? You had plenty of chances with all of your FUD , naked shorting drop stock prices. With The New Hires & Conference Call tomorrow, there is obvious Bullish updates. Stan...
4
3
101682201-dna
liked
$Cassava Sciences (SAVA.US)$ We do need Someone better at SEC that will actually hold the naked shorting accountable. SAVA bullish
11
2
101682201-dna
liked
$Cassava Sciences (SAVA.US)$ Thanks to Matt. Patient testimony and documentary out today. SAVA AD patients will not be silenced as this is improving many people. Shorts/HF you are done with all of your lies and cheating and the delays of trials as Even today Clinical Trials Update marked as Completed
7
101682201-dna
liked
$Cassava Sciences (SAVA.US)$Manny's story is inspiration. 90 Years Old. SAVA has made a difference in his life and the lives of his family members to enjoy more moments. You cannot deny the impact . This is safe and needed. Thanks to Matt, Manny's Daughter, Family and Manny for showing us there is hope on the horizon. All of those who lost their lives and didn't get proper time with their families. We hope that others in the future will benefit from SAVA and spend more quality time with their fa...
7
101682201-dna
liked
$Cassava Sciences (SAVA.US)$ Bullish Update :Completed
Simufilam 100 Mg for Mild-to-Moderate Alzheimer's Disease(RETHINK-ALZ)
ClinicalTrials.gov ID NCT04994483
Sponsor Cassava Sciences, Inc.
Information provided by Cassava Sciences, Inc.(Responsible Party)
Last Update Posted 2024-11-15
Simufilam 100 Mg for Mild-to-Moderate Alzheimer's Disease(RETHINK-ALZ)
ClinicalTrials.gov ID NCT04994483
Sponsor Cassava Sciences, Inc.
Information provided by Cassava Sciences, Inc.(Responsible Party)
Last Update Posted 2024-11-15
5